DecImmune Therapeutics Lands $1,000,000 New Funding Round

  • Feed Type
  • Date
    9/27/2010
  • Company Name
    DecImmune Therapeutics
  • Mailing Address
    One Blackfan Circle Rm. 10217 Boston, MA 02115
  • Company Description
    The company operates as a drug development company focused on inflammation.
  • Website
    http://www.decimmune.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The new funds will enable accelerated development of the company’s proprietary technology to reduce tissue damage, accelerate healing, and improve outcomes associated with ischemia reperfusion injury.
  • M&A Terms
  • Venture Investor
    Astellas Venture Management LLC
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Amgen Ventures

Next Post

Related Topics

Related Posts

Xconomy’s Most Popular

  1. Don’t Panic, But We’ve Passed Peak Apple. And Google. And Facebook.
  2. With Big Bucks Chasing Big Data, Will Consumers Get a Cut?
  3. Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
  4. 11 Reasons Why Flickr, Not Facebook, Is the Place to Put Your Photos
  5. Digital Lumens, Finding Its Identity, Brings Cost & Energy Savings to Light

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.